Mizuho analyst Irina Koffler raised her price target for Ironwood Pharmaceuticals to $20 to reflect higher anticipated collaboration value in China and the Cyclerion spin. The analyst also expects Ironwood to beat Q4 consensus estimates. She reiterates a Buy rating on the shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.